PharmaMar Increases its Treasury Shares Above 4%, a Historical Maximum

PharmaMar has increased its treasury stock to 4.37% of the group’s capital, from the previous 3.55%, which represents a historical maximum since there are records , according to the information sent this Tuesday to the National Securities Market Commission (CNMV). ).

This operation has occurred after the completion of its share buyback program at the end of January, which had a maximum extension of six months and concluded with the acquisition of 2.28% of its share capital , that is, a total of 419,400 own titles.

The operations for the acquisition or transfer of shares dated January 30th, 2024, of 659 shares and February 20, 2024, of twenty shares , correspond to operations carried out directly by PharmaMar or indirectly by the group companies, within the framework of the free share delivery plans approved by the company.

Likewise, the company, direct owner of 100% of the share capital of Sylentis and Genómica, has detailed that Sylentis is the owner of 284 shares of PharmaMar and Genómica , of 115 shares, both as a consequence of the voluntary resignation of some of its employees and in implementation of group delivery plans.

Read more about PharmaMar and find the most important business news of the day with our companion app Born2Invest, available for free for both Android and iOS devices.

PharmaMar closed the last fiscal year with a drop in net profit of 98% compared to 2022

PharmaMar closed 2023 with a net profit of 1.14 million euros, which represents a decrease of almost 98% compared to the previous year , when it earned 49.36 million euros. The company recorded total revenues of 158.15 million euros, 19.45% less, due to the impact of the arrival of the generic trabectedin to the European market.

The Spanish biotechnology company started February with falls of almost 3% at the opening of the market . The reason was that Sylentis had failed in its primary objective of developing a drug indicated to treat dry eye, associated with Sjögren’s syndrome. Sylentis’ notice to the CNMV triggered a fall in the shares of its company that owns it by 2.98 %, lowering the share price to 35.2 euros, but later the fall was reduced to 1.32% , which left the shares at 35.8 euros.

The clinical trials knocked down the PharmaMar drug in its third phase, after some 230 patients from forty hospitals in the United States and eight in Spain participated in them. All tests were carried out in a randomized, double-blind and placebo-controlled manner.

__

(Featured image by Robert Anasch via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us